Recombinant MACFA TTR Protein，His

Transferrin receptor (TTR) is an important protein involved in the transport of retinol and thyroxine, primarily synthesized in the liver and the choroid plexus of the brain. Recent studies have highlighted its role in various pathological conditions, including neurodegenerative diseases, amyloidosis, and metabolic disorders. TTR itself can misfold and aggregate, leading to the formation of amyloid deposits that can severely compromise organ function. This has spurred research into TTR as a potential therapeutic target, as well as a candidate for recombinant protein studies. Understanding the molecular mechanisms of TTR misfolding and aggregation is essential for developing effective treatments. Recombinant proteins, particularly engineered variants of TTR, are being explored for their ability to stabilize its structure and inhibit amyloid formation. Furthermore, advancements in recombinant DNA technology have enabled the production of various TTR isoforms with specific modifications that could enhance their therapeutic potential. The investigation of TTR recombinant proteins is thus critical, not only for elucidating TTR’s biological functions but also for developing practical applications in drug design and therapeutic interventions for diseases associated with TTR dysfunction.